Breast cancer is a leading cause of cancer death among women. Antiestrogen drugs, such as tamoxifen (Tam), are effective in the treatment of estrogen receptor alpha (ER)-positive breast tumors by slowing the growth of the tumors, preventing the recurrence of the disease, and with relatively few side effects. However, almost all responsive tumors eventually develop of Tam-resistance. The mechanism(s) responsible for resistance and/or growth promoting effects of Tam are not clear at present. Studies from our group and others indicated estrogen-induced MAPK activation (Erk 1&2) is predominantly mediated by HRG/HER-2/PKC-delta/Ras pathway. We have recently shown the following: (a) Three out of four antiestrogen resistant cell lines overexpress total and activated PKC-delta, (b) Overexpression of PKC-delta in Tam-sensitive MCF-7 cells leads to Tam-resistance both in vitro and in vivo, (c) Inhibition of PKC-delta by rottlerin or siRNA significantly reversed antiestrogen resistance, (d) Pretreatment of cells with rottlerin followed by TRAIL significantly enhanced apoptosis in antiestrogen resistant cells compared with sensitive cells in vitro, (e) PKC-delta levels are higher in Tam-resistant tumors compared to Tam-sensitive tumors in MCF-7 tumor xenograft, (f) Immunohistochemical staining of Tam-resistant human breast tumors showed a significant increase of PKC-delta levels compared with those in Tam-sensitive tumors. Based on the above results, we hypothesize that overexpression and/or activation of PKC-delta plays a major role in the regulation of antiestrogen resistance in ER-positive breast tumor cells. We are proposing the following four specific aims to test our hypotheses:
Aim 1. We will determine the molecular mechanism by which PKC-delta overexpression and/or activation suppresses apoptosis in antiestrogen resistant cell lines.
Aim 2. We will investigate how PKC-delta and/or its down stream signaling molecules regulate antiestrogen resistance.
Aim 3. We will determine mechanism by which PKC-delta inhibitors sensitizes antiestrogen resistant cells to TRAIL-induced apoptosis.
Aim 4. We will develop treatment strategies to translate in vitro observations into practically applicable therapies in vivo. We anticipate that the proposed investigations would reveal novel insights into the mechanism by which PKC-delta regulates antiestrogen-resistance and the data should provide defined molecular target(s) for future clinical intervention for the treatment of breast cancer. ? ? ? ?
| Yin, Shuping; Xu, Liping; Bonfil, R Daniel et al. (2013) Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol Cancer Ther 12:491-8 |
| Reddy, K B (2011) Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 18:e173-9 |
| Yin, Shuping; Xu, Liping; Bandyopadhyay, Sudeshna et al. (2011) Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol 39:891-8 |
| Xu, Liping; Yin, Shuping; Banerjee, Sanjeev et al. (2011) Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol Cancer Ther 10:550-7 |
| Yin, Shuping; Sethi, Seema; Reddy, Kaladhar B (2010) Protein kinase C? and caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. J Cell Biochem 111:979-87 |
